NewAmsterdam Pharma Company N.V. NAMS
19.90 USD +0.34 (+1.74%)
At closeNov 3, 2026, 4:23 PM EST
19.90 0.00 0.00%
After hours · Nov 3, 4:23 PM ET
19.59 Day range 20.46
19.13 52-week range 42.21
- YTD
- -43.27%
- 1 year
- -46.22%
Financial health
Altman Z-Score
17.28 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 1
Valuation
P/E -20.0×
FY 2020 5y median -9.2× FY 2025
P/S 178×
FY 2020 5y median 53.2× FY 2025
P/B 5.9×
FY 2020 5y median 3.2× FY 2025
P/FCF -27.1×
FY 2020 5y median -6.5× FY 2025
EV/EBITDA -14.5×
FY 2020 5y median -3.3× FY 2025
EV/Sales 157×
FY 2020 5y median 36.3× FY 2025
FCF Yield -3.7%
FY 2020 5y median -6.6% FY 2025
Profitability
Gross Margin 99.7%
FY 2020 5y median 100.0% FY 2025
Operating Margin -1002.9%
FY 2020 5y median -386.9% FY 2025
Net Margin -905.7%
FY 2020 5y median -530.3% FY 2025
ROE -29.8%
FY 2020 5y median -31.9% FY 2025
ROIC -33.0%
FY 2020 5y median -33.0% FY 2025
ROA -26.5%
FY 2020 5y median -27.9% FY 2025
Growth (YoY)
Revenue -50.6%
FY 2020 FY 2025
Operating Income -28.0%
FY 2020 FY 2025
EPS (diluted) 31.6%
FY 2020 FY 2025
Free Cash Flow 7.0%
FY 2020 FY 2025
Financial Health
Current Ratio 7.9×
FY 2020 5y median 7.9× FY 2025
Quick Ratio 7.9×
FY 2020 5y median 7.9× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 2.0×
FY 2020 5y median 2.0× FY 2025
Interest Coverage 0.0×
FY 2020 5y median -12.4× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31